// App-Quantinova.ai

: A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis (RRMS) (P1.369)

Researchers

Presenter

  • Timothy Spelman

Principal Investigators

  • Dana Horakova

  • Maria Trojano

  • Alessandra Lugaresi

  • Guillermo Izquierdo

  • Pierre Grammond

  • Pierre Duquette

  • Raed Alroughani

  • Eugenio Pucci

  • Franco Granella

  • Jeannette Lechner-Scott

  • Patrizia Sola

  • Diana Ferraro

  • Franois GrandMaison

  • Murat Terzi

  • Csilla Rozsa

  • Cavit Boz

  • Raymond Hupperts

  • Vincent Van Pesch

  • Celia Oreja-Guevara

  • Vilija Jokubaitis

  • Tomas Kalincik

  • Helmut Butzkueven

Medical Centers

  • 20Maaslandziekenhuis Sittard Netherlands

  • John Hunter Hospital, Newcastle, Australia

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

  • 11Neurology Unit, ASUR Marche – AV3 Macerata Italy

  • Department of Medicine, University of Melbourne, Melbourne, Australia

  • 14Nuovo Ospedale Civile Sant’ Agostino/Estense Modena Italy

  • 16Neuro Rive-Sud, Hôpital Charles LeMoyne Greenfield Park QC Canada

  • Department of Basic Medical Sciences, Neurosciences and Sense Organs University of Bari, Italy, Bari, Italy

  • Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia

  • 4Department of Neurology and Center of Clinical Neuroscience, 1st Faculty of Medicine, General University Hospital and Charles University in Prague Prague Czech Republic

  • Royal Melbourne Hospital, Melbourne, Australia

  • 8Center de réadaptation déficience physique Chaudière-Appalache Lévis QC Canada

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

  • Amiri Hospital, Kuwait City, Kuwait

  • Biochemistry, Karadeniz Technical University, Trabzon, Turkey

  • 18Jahn Ferenc Teaching Hospital Budapest Hungary

  • 9Hôpital Notre Dame Montreal QC Canada

  • 6MS Center, Department of Neuroscience and Imaging, University ‘G. d’Annunzio’ Chieti Italy

  • 19 Mayis Universitesi Samsun Turkey

  • Hospital Clinico Universitario San Carlos, Madrid, Spain

  • University Hospital of Parma, Parma, Italy

  • Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia

Locations

  • Netherlands

  • Australia

  • Spain

  • Italy

  • Canada

  • Belgium

  • Kuwait

  • Turkey

  • Hungary

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Natalizumab

  • Fingolimod

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved